Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year?
ALX Oncology Holdings Inc. (ALXO) Q1 2026 Earnings Call Transcript
ALX Oncology Q1 Earnings Call Highlights
ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update
ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update
ALX Oncology's Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression
ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Short Interest Update
ALX Oncology Q4 Earnings Call Highlights
ALX Oncology Holdings Inc. (ALXO) Q4 2025 Earnings Call Transcript
ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026
ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026
Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year?
Corey Goodman Acquires 3,184,713 Shares of ALX Oncology (NASDAQ:ALXO) Stock
Market Today: Tech Slump, Google AI Spend, Bitcoin Slide
ALX Oncology Announces Pricing of Underwritten Offering
New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology's Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer
ALX Oncology Holdings Inc. (ALXO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference
ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of “Moderate Buy” by Brokerages
Short Interest in ALX Oncology Holdings Inc. (NASDAQ:ALXO) Expands By 32.0%
ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting
ALX Oncology to Present at Upcoming Investor Conferences
ALX Oncology Holdings Inc. (ALXO) Q3 2025 Earnings Call Transcript
ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update
ALX Oncology (ALXO) Expected to Announce Earnings on Friday
ALX Oncology to Report Third Quarter 2025 Financial Results and Pipeline Progress Including Evorpacept CD47 Biomarker Data to be Presented at Upcoming SITC Annual Meeting
ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference
ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer
ALX Oncology to Participate in Upcoming Investor Conferences in September
ALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid Tumors
ALX Oncology Holdings Inc. (ALXO) Q2 2025 Earnings Call Transcript
ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update
ALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025
ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference
ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event
ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025
ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update
ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025
ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma
ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints
ALX Oncology Holdings (ALXO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event
ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025